Doc, here's a stab at a medium-term (18 months?) m
Post# of 36537
(Total Views: 338)
Posted On: 05/11/2021 11:35:12 AM
Doc, here's a stab at a medium-term (18 months?) model for the RPM, using your input.
Sunjay was emphatic that he would not sign contracts unless they were the "desired contracts". So let's say they achieve somewhere toward the more beneficial end of your range, and the medical practice takes 40%.
Then assume an even split with WWDC (unknown) on the remaining 60%... giving NGH 30% of revs.
If the initial 6 month rollout is successful, and they can take their case to a broader market, let's say they can get to 50k patients 18 months from now. The numbers would be:
50k patients x $115/mo x 12 months = $69MM in total annual revs
= $20.7MM in annual revs for NGH
= ~$14.5MM in annual cash flow for NGH.
So if we pair that w Excellagen's revenues in 18 months, we're a functioning business regardless of vaccine outcomes.
Sunjay was emphatic that he would not sign contracts unless they were the "desired contracts". So let's say they achieve somewhere toward the more beneficial end of your range, and the medical practice takes 40%.
Then assume an even split with WWDC (unknown) on the remaining 60%... giving NGH 30% of revs.
If the initial 6 month rollout is successful, and they can take their case to a broader market, let's say they can get to 50k patients 18 months from now. The numbers would be:
50k patients x $115/mo x 12 months = $69MM in total annual revs
= $20.7MM in annual revs for NGH
= ~$14.5MM in annual cash flow for NGH.
So if we pair that w Excellagen's revenues in 18 months, we're a functioning business regardless of vaccine outcomes.
(5)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼